Shopping Cart 0
Cart Subtotal
USD 0

Ovarian Cancer-Pipeline Review, H2 2017

Restricted to one authorized user; Open on 1 PC/ mobile / Tablet only.
Print Option: Yes
Copy Option: No
Deliverable Format : PDF Via Email

Single User License
USD 2500

Restricted to one authorized user; Open on 1 PC/ mobile / Tablet only.
Print Option: Yes
Copy Option: No
Deliverable Format : PDF Via Email

Site License
USD 5000

Multiple Users within the Company/ Enterprise
Print Option: Yes
Copy Option: Yes
Deliverable Format : Excel, PDF Via Email

Corporate User License
USD 7500
  • Details
  • Table Of Content
  • Licence Rights
  • Section Purchase
  • Products and Companies

Details

Ovarian Cancer-Pipeline Review, H2 2017

Summary

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Ovarian Cancer-Pipeline Review, H2 2017, provides an overview of the Ovarian Cancer (Oncology) pipeline landscape.

Ovarian cancer is any cancerous growth that may occur in different parts of the ovary. The majority of ovarian cancers arise from the epithelium (outer lining) of the ovary. Signs and symptoms of ovarian cancer include pelvic discomfort or pain, indigestion, gas or nausea, changes in bowel habits, such as constipation, loss of appetite and low back pain. The predisposing factors include age and family history. Treatment includes surgery, chemotherapy and radiation therapy.

Report Highlights

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Ovarian Cancer-Pipeline Review, H2 2017, provides comprehensive information on the therapeutics under development for Ovarian Cancer (Oncology), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Ovarian Cancer (Oncology) pipeline guide also reviews of key players involved in therapeutic development for Ovarian Cancer and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Pre-Registration, Filing rejected/Withdrawn, Phase III, Phase II, Phase I, IND/CTA Filed, Preclinical, Discovery and Unknown stages are 5, 2, 14, 141, 144, 7, 221, 26 and 10 respectively. Similarly, the Universities portfolio in Phase II, Phase I, Preclinical and Discovery stages comprises 10, 12, 45 and 8 molecules, respectively.

Ovarian Cancer (Oncology) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct'sproprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope

The pipeline guide provides a snapshot of the global therapeutic landscape of Ovarian Cancer (Oncology).

The pipeline guide reviews pipeline therapeutics for Ovarian Cancer (Oncology) by companies and universities/research institutes based on information derived from company and industry-specific sources.

The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.

The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.

The pipeline guide reviews key companies involved in Ovarian Cancer (Oncology) therapeutics and enlists all their major and minor projects.

The pipeline guide evaluates Ovarian Cancer (Oncology) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.

The pipeline guide encapsulates all the dormant and discontinued pipeline projects.

The pipeline guide reviews latest news related to pipeline therapeutics for Ovarian Cancer (Oncology)

Reasons to buy

Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.

Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.

Find and recognize significant and varied types of therapeutics under development for Ovarian Cancer (Oncology).

Classify potential new clients or partners in the target demographic.

Develop tactical initiatives by understanding the focus areas of leading companies.

Plan mergers and acquisitions meritoriously by identifying key players and it'smost promising pipeline therapeutics.

Formulate corrective measures for pipeline projects by understanding Ovarian Cancer (Oncology) pipeline depth and focus of Indication therapeutics.

Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.

Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

READ MORE

Table Of Content

Scope

Table of Contents

Table of Contents

Introduction

Ovarian Cancer-Overview

Ovarian Cancer-Therapeutics Development

Ovarian Cancer-Therapeutics Assessment

Ovarian Cancer-Companies Involved in Therapeutics Development

Ovarian Cancer-Drug Profiles

Ovarian Cancer-Dormant Projects

Ovarian Cancer-Discontinued Products

Ovarian Cancer-Product Development Milestones

Appendix


List Of Figure

List of Figures

Number of Products under Development for Ovarian Cancer, H2 2017

Number of Products under Development by Companies, H2 2017

Number of Products under Development by Universities/Institutes, H2 2017

Number of Products by Top 10 Targets, H2 2017

Number of Products by Stage and Top 10 Targets, H2 2017

Number of Products by Top 10 Mechanism of Actions, H2 2017

Number of Products by Stage and Top 10 Mechanism of Actions, H2 2017

Number of Products by Routes of Administration, H2 2017

Number of Products by Stage and Routes of Administration, H2 2017

Number of Products by Top 10 Molecule Types, H2 2017

Number of Products by Stage and Top 10 Molecule Types, H2 2017


List Of Table

List of Tables

Number of Products under Development for Ovarian Cancer, H2 2017

Number of Products under Development by Companies, H2 2017

Number of Products under Development by Universities/Institutes, H2 2017

Products under Development by Companies, H2 2017

Products under Development by Universities/Institutes, H2 2017

Number of Products by Stage and Target, H2 2017

Number of Products by Stage and Mechanism of Action, H2 2017

Number of Products by Stage and Route of Administration, H2 2017

Number of Products by Stage and Molecule Type, H2 2017

Ovarian Cancer-Pipeline by 3-V Biosciences Inc, H2 2017

Ovarian Cancer-Pipeline by 4SC AG, H2 2017

Ovarian Cancer-Pipeline by AB Science SA, H2 2017

Ovarian Cancer-Pipeline by AbbVie Inc, H2 2017

Ovarian Cancer-Pipeline by AbGenomics International Inc, H2 2017

Ovarian Cancer-Pipeline by Adaptimmune Therapeutics Plc, H2 2017

Ovarian Cancer-Pipeline by Adgero Biopharmaceuticals Holdings Inc, H2 2017

Ovarian Cancer-Pipeline by Advanced Cancer Therapeutics LLC, H2 2017

Ovarian Cancer-Pipeline by Advantagene Inc, H2 2017

Ovarian Cancer-Pipeline by Advenchen Laboratories LLC, H2 2017

Ovarian Cancer-Pipeline by Aeterna Zentaris Inc, H2 2017

Ovarian Cancer-Pipeline by Alethia Biotherapeutics Inc, H2 2017

Ovarian Cancer-Pipeline by AlfaSigma SpA, H2 2017

Ovarian Cancer-Pipeline by Alkermes Plc, H2 2017

Ovarian Cancer-Pipeline by Allist Shanghai Pharmaceutical Technology Co Ltd, H2 2017

Ovarian Cancer-Pipeline by Almac Discovery Ltd, H2 2017

Ovarian Cancer-Pipeline by Alpha Cancer Technologies Inc, H2 2017

Ovarian Cancer-Pipeline by Alteogen Inc, H2 2017

Ovarian Cancer-Pipeline by Altor BioScience Corp, H2 2017

Ovarian Cancer-Pipeline by Ambrx Inc, H2 2017

Ovarian Cancer-Pipeline by Amgen Inc, H2 2017

Ovarian Cancer-Pipeline by Amunix Operating Inc, H2 2017

Ovarian Cancer-Pipeline by Anavex Life Sciences Corp, H2 2017

Ovarian Cancer-Pipeline by ANP Technologies Inc, H2 2017

Ovarian Cancer-Pipeline by AntiCancer Inc, H2 2017

Ovarian Cancer-Pipeline by Antigen Express Inc, H2 2017

Ovarian Cancer-Pipeline by Antoxis Ltd, H2 2017

Ovarian Cancer-Pipeline by Aphios Corp, H2 2017

Ovarian Cancer-Pipeline by Aposense Ltd, H2 2017

Ovarian Cancer-Pipeline by Aprea AB, H2 2017

Ovarian Cancer-Pipeline by arGEN-X BV, H2 2017

Ovarian Cancer-Pipeline by ARMO Biosciences Inc, H2 2017

Ovarian Cancer-Pipeline by Armour Therapeutics Inc, H2 2017

Ovarian Cancer-Pipeline by ArQule Inc, H2 2017

Ovarian Cancer-Pipeline by Array BioPharma Inc, H2 2017

Ovarian Cancer-Pipeline by Arrien Pharmaceuticals LLC, H2 2017

Ovarian Cancer-Pipeline by Astellas Pharma Inc, H2 2017

Ovarian Cancer-Pipeline by Astex Pharmaceuticals Inc, H2 2017

Ovarian Cancer-Pipeline by AstraZeneca Plc, H2 2017

Ovarian Cancer-Pipeline by Atara Biotherapeutics Inc, H2 2017

Ovarian Cancer-Pipeline by Athenex Inc, H2 2017

Ovarian Cancer-Pipeline by AVEO Pharmaceuticals Inc, H2 2017

Ovarian Cancer-Pipeline by Avipep Pty Ltd, H2 2017

Ovarian Cancer-Pipeline by Basilea Pharmaceutica Ltd, H2 2017

Ovarian Cancer-Pipeline by Bavarian Nordic A/S, H2 2017

Ovarian Cancer-Pipeline by Bayer AG, H2 2017

Ovarian Cancer-Pipeline by BeiGene Ltd, H2 2017

Ovarian Cancer-Pipeline by Bio-Path Holdings Inc, H2 2017

Ovarian Cancer-Pipeline by BioCancell Ltd, H2 2017

Ovarian Cancer-Pipeline by BioMoti Ltd, H2 2017

Ovarian Cancer-Pipeline by Bionomics Ltd, H2 2017

Ovarian Cancer-Pipeline by BioNTech AG, H2 2017

Ovarian Cancer-Pipeline by Biscayne Pharmaceuticals Inc, H2 2017

Ovarian Cancer-Pipeline by Boehringer Ingelheim GmbH, H2 2017

Ovarian Cancer-Pipeline by Boston Biomedical Inc, H2 2017

Ovarian Cancer-Pipeline by Bristol-Myers Squibb Co, H2 2017

Ovarian Cancer-Pipeline by Caladrius Biosciences Inc, H2 2017

Ovarian Cancer-Pipeline by Calithera Biosciences Inc, H2 2017

Ovarian Cancer-Pipeline by CASI Pharmaceuticals Inc, H2 2017

Ovarian Cancer-Pipeline by Cavion LLC, H2 2017

Ovarian Cancer-Pipeline by CBT Pharmaceuticals Inc, H2 2017

Ovarian Cancer-Pipeline by Celgene Corp, H2 2017

Ovarian Cancer-Pipeline by Celldex Therapeutics Inc, H2 2017

Ovarian Cancer-Pipeline by Celleron Therapeutics Ltd, H2 2017

Ovarian Cancer-Pipeline by Cellular Biomedicine Group Inc, H2 2017

Licence Rights

Single User License:
Report can be used by individual purchaser only

Site License: 
Report can be shared by unlimited users within one corporate location, e.g. a regional office

Corporate User License:  
Report can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company

Section Purchase

To know more information on Purchase by Section, please send a mail to support@kenresearch.com

Products and Companies


Companies

3-V Biosciences Inc

4SC AG

AB Science SA

AbbVie Inc

AbGenomics International Inc

Adaptimmune Therapeutics Plc

Adgero Biopharmaceuticals Holdings Inc

Advanced Cancer Therapeutics LLC

Advantagene Inc

Advenchen Laboratories LLC

Aeterna Zentaris Inc

Alethia Biotherapeutics Inc

AlfaSigma SpA

Alkermes Plc

Allist Shanghai Pharmaceutical Technology Co Ltd

Almac Discovery Ltd

Alpha Cancer Technologies Inc

Alteogen Inc

Altor BioScience Corp

Ambrx Inc

Amgen Inc

Amunix Operating Inc

Anavex Life Sciences Corp

ANP Technologies Inc

AntiCancer Inc

Antigen Express Inc

Antoxis Ltd

Aphios Corp

Aposense Ltd

Aprea AB

arGEN-X BV

ARMO Biosciences Inc

Armour Therapeutics Inc

ArQule Inc

Array BioPharma Inc

Arrien Pharmaceuticals LLC

Astellas Pharma Inc

Astex Pharmaceuticals Inc

AstraZeneca Plc

Atara Biotherapeutics Inc

Athenex Inc

AVEO Pharmaceuticals Inc

Avipep Pty Ltd

Basilea Pharmaceutica Ltd

Bavarian Nordic A/S

Bayer AG

BeiGene Ltd

Bio-Path Holdings Inc

BioCancell Ltd

BioMoti Ltd

Bionomics Ltd

BioNTech AG

Biscayne Pharmaceuticals Inc

Boehringer Ingelheim GmbH

Boston Biomedical Inc

Bristol-Myers Squibb Co

Caladrius Biosciences Inc

Calithera Biosciences Inc

CASI Pharmaceuticals Inc

Cavion LLC

CBT Pharmaceuticals Inc

Celgene Corp

Celldex Therapeutics Inc

Celleron Therapeutics Ltd

Cellular Biomedicine Group Inc

Celon Pharma SA

Celprogen Inc

Celsion Corp

Celyad SA

Ceronco Biosciences

CerRx Inc

Chipscreen Biosciences Ltd

Cielo Therapeutics Inc

Clovis Oncology Inc

CohBar Inc

Coherus BioSciences Inc

Commence Bio Inc

Compliment Corp

Corcept Therapeutics Inc

Critical Outcome Technologies Inc

Cyclacel Pharmaceuticals Inc

CytomX Therapeutics Inc

Cytori Therapeutics Inc

CZ BioMed Corp

DAE HWA Pharmaceutical Co Ltd

Deciphera Pharmaceuticals LLC

DEKK-TEC Inc

DelMar Pharmaceuticals Inc

Dr. Reddy's Laboratories Ltd

Ecrins Therapeutics SAS

Eisai Co Ltd

Eli Lilly and Co

Endocyte Inc

EntreChem SL

Epigen Biosciences Inc

EpiThany Inc

Epizyme Inc

Esperance Pharmaceuticals Inc

Exelixis Inc

F. Hoffmann-La Roche Ltd

Faron Pharmaceuticals Oy

Fate Therapeutics Inc

Forty Seven Inc

Fujifilm Holdings Corporation

Galena Biopharma Inc

GamaMabs Pharma SA

Gene Techno Science Co Ltd

Genelux Corp

Genentech Inc

Genisphere LLC

Genmab A/S

Genor BioPharma Co Ltd

Gilead Sciences Inc

GlaxoSmithKline Plc

Glenmark Pharmaceuticals Ltd

GlycoNex Inc

Glycotope GmbH

GP Pharm SA

Gradalis Inc

GW Pharmaceuticals Plc

Halozyme Therapeutics Inc

Hanmi Pharmaceuticals Co Ltd

Hemispherx Biopharma Inc

Horizon Pharma Plc

Ideaya Biosciences Inc

Ignyta Inc

Ildong Pharmaceutical Co Ltd

IMMD Inc

Immix BioPharma Inc

Immune Design Corp

Immune Pharmaceuticals Inc

Immunocore Ltd

ImmunoGen Inc

Immunomedics Inc

Immunovaccine Inc

IMPACT Therapeutics Inc

Imugene Ltd

Incyte Corp

Innate Pharma SA

Innovation Pharmaceuticals Inc

Inovio Pharmaceuticals Inc

Inventiva

Iovance Biotherapeutics Inc

ITUS Corp

Jiangsu Hengrui Medicine Co Ltd

Jiangsu Kanion Pharmaceutical Co Ltd

Johnson & Johnson

Juno Therapeutics Inc

Karyopharm Therapeutics Inc

Kazia Therapeutics Ltd

Kringle Pharma Inc

Kyowa Hakko Kirin Co Ltd

La Jolla Pharmaceutical Company

Laboratoire HRA Pharma SAS

Lantern Pharma Inc

LATITUDE Pharmaceuticals Inc

LegoChem Biosciences Inc

Lidds AB

Lixte Biotechnology Holdings Inc

Loxo Oncology Inc

Lycera Corp

Lymphocyte Activation Technologies SA

MabVax Therapeutics Holdings Inc

MacroGenics Inc

Madrigal Pharmaceuticals Inc.

Mateon Therapeutics Inc

MaxiVAX SA

Mebiopharm Co Ltd

MediaPharma SRL

MedImmune LLC

Medivir AB

Merck & Co Inc

Merck KGaA

Merrimack Pharmaceuticals Inc

Mersana Therapeutics Inc

Merus NV

Microlin Bio Inc

Millennium Pharmaceuticals Inc

Minerva Biotechnologies Corp

Moleculin Biotech Inc

MolMed SpA

Monopar Therapeutics LLC

Morphotek Inc

Mycenax Biotech Inc

NanoVector Inc

NantKwest Inc

Natco Pharma Ltd

NBE-Therapeutics AG

Nektar Therapeutics

Neovacs SA

Nerviano Medical Sciences Srl

Neurimmune Holding AG

NewLink Genetics Corp

Northwest Biotherapeutics Inc

Novartis AG

NovaTarg Therapeutics Inc

Noviga Research AB

Noxopharm Ltd

NuCana Plc

Oasmia Pharmaceutical AB

OBI Pharma Inc

Omeros Corp

Omnitura Therapeutics Inc

OncBioMune Pharmaceuticals Inc

Oncobiologics Inc

Oncodesign SA

Oncolix Inc

Oncolytics Biotech Inc

OncoMed Pharmaceuticals Inc

OncoResponse Inc

OncoTartis Inc

OncoTherapy Science Inc

Oncternal Therapeutics Inc

Ono Pharmaceutical Co Ltd

Opsona Therapeutics Ltd

Optimum Therapeutics LLC

ORCA Therapeutics BV

Oric Pharmaceuticals Inc

OSE Immunotherapeutics

Oxford BioMedica Plc

Pangaea Biotech SL

Patrys Ltd

PDS Biotechnology Corp

PEP-Therapy SAS

Pfizer Inc

Pharma Mar SA

PharmAust Ltd

Pharmicell Co Ltd

Plexxikon Inc

Polaris Pharmaceuticals Inc

Precision Biologics Inc

Propanc Biopharma Inc

Protheragen Inc

PsiOxus Therapeutics Ltd

PTC Therapeutics Inc

Puma Biotechnology Inc

Radius Health Inc

Recepta Biopharma SA

Rexahn Pharmaceuticals Inc

Rgenix Inc

Richter Gedeon Nyrt

Rigel Pharmaceuticals Inc

Rosetta Genomics Ltd

RS Research

Rubicon Biotechnology Inc

RXi Pharmaceuticals Corp

Samumed LLC

Sanofi

Sanofi Pasteur SA

SATT North SAS

Scancell Holdings Plc

Sellas Life Sciences Group Ltd

Senhwa Biosciences Inc

Sequoia Sciences Inc

Siamab Therapeutics Inc

Sierra Oncology Inc

Sigma-Tau SpA

Sillajen Biotherapeutics

Sitka Biopharma Inc

Soricimed Biopharma Inc

Sorrento Therapeutics Inc

Sotio AS

Starpharma Holdings Ltd

Sumitomo Dainippon Pharma Co Ltd

Sun Pharma Advanced Research Company Ltd

Supratek Pharma Inc

Susavion Biosciences Inc

Sutro Biopharma Inc

Syndax Pharmaceuticals Inc

Synthon Holdings BV

Syros Pharmaceuticals Inc

Tactiva Therapeutics LLC

Taiho Pharmaceutical Co Ltd

Takis Srl

TapImmune Inc

Targovax ASA

TC BioPharm Ltd

Tesaro Inc

The Female Health Company

TheraTarget Inc

Tocagen Inc

TRACON Pharmaceuticals Inc

Transgene SA

TVAX Biomedical Inc

Tyrogenex Inc

Unleash Immuno Oncolytics Inc

ValiRx Plc

Vascular Biogenics Ltd

Vectorite Biomedical Inc

Verastem Inc

VG Life Sciences Inc

ViiV Healthcare UK Ltd

ViraTherapeutics GmbH

Vyriad Inc

Zymeworks Inc

Ovarian Cancer-Pipeline Review, H2 2017

Summary

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Ovarian Cancer-Pipeline Review, H2 2017, provides an overview of the Ovarian Cancer (Oncology) pipeline landscape.

Ovarian cancer is any cancerous growth that may occur in different parts of the ovary. The majority of ovarian cancers arise from the epithelium (outer lining) of the ovary. Signs and symptoms of ovarian cancer include pelvic discomfort or pain, indigestion, gas or nausea, changes in bowel habits, such as constipation, loss of appetite and low back pain. The predisposing factors include age and family history. Treatment includes surgery, chemotherapy and radiation therapy.

Report Highlights

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Ovarian Cancer-Pipeline Review, H2 2017, provides comprehensive information on the therapeutics under development for Ovarian Cancer (Oncology), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Ovarian Cancer (Oncology) pipeline guide also reviews of key players involved in therapeutic development for Ovarian Cancer and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Pre-Registration, Filing rejected/Withdrawn, Phase III, Phase II, Phase I, IND/CTA Filed, Preclinical, Discovery and Unknown stages are 5, 2, 14, 141, 144, 7, 221, 26 and 10 respectively. Similarly, the Universities portfolio in Phase II, Phase I, Preclinical and Discovery stages comprises 10, 12, 45 and 8 molecules, respectively.

Ovarian Cancer (Oncology) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct'sproprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope

The pipeline guide provides a snapshot of the global therapeutic landscape of Ovarian Cancer (Oncology).

The pipeline guide reviews pipeline therapeutics for Ovarian Cancer (Oncology) by companies and universities/research institutes based on information derived from company and industry-specific sources.

The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.

The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.

The pipeline guide reviews key companies involved in Ovarian Cancer (Oncology) therapeutics and enlists all their major and minor projects.

The pipeline guide evaluates Ovarian Cancer (Oncology) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.

The pipeline guide encapsulates all the dormant and discontinued pipeline projects.

The pipeline guide reviews latest news related to pipeline therapeutics for Ovarian Cancer (Oncology)

Reasons to buy

Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.

Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.

Find and recognize significant and varied types of therapeutics under development for Ovarian Cancer (Oncology).

Classify potential new clients or partners in the target demographic.

Develop tactical initiatives by understanding the focus areas of leading companies.

Plan mergers and acquisitions meritoriously by identifying key players and it'smost promising pipeline therapeutics.

Formulate corrective measures for pipeline projects by understanding Ovarian Cancer (Oncology) pipeline depth and focus of Indication therapeutics.

Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.

Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

READ MORE

Scope

Table of Contents

Table of Contents

Introduction

Ovarian Cancer-Overview

Ovarian Cancer-Therapeutics Development

Ovarian Cancer-Therapeutics Assessment

Ovarian Cancer-Companies Involved in Therapeutics Development

Ovarian Cancer-Drug Profiles

Ovarian Cancer-Dormant Projects

Ovarian Cancer-Discontinued Products

Ovarian Cancer-Product Development Milestones

Appendix


List Of Figure

List of Figures

Number of Products under Development for Ovarian Cancer, H2 2017

Number of Products under Development by Companies, H2 2017

Number of Products under Development by Universities/Institutes, H2 2017

Number of Products by Top 10 Targets, H2 2017

Number of Products by Stage and Top 10 Targets, H2 2017

Number of Products by Top 10 Mechanism of Actions, H2 2017

Number of Products by Stage and Top 10 Mechanism of Actions, H2 2017

Number of Products by Routes of Administration, H2 2017

Number of Products by Stage and Routes of Administration, H2 2017

Number of Products by Top 10 Molecule Types, H2 2017

Number of Products by Stage and Top 10 Molecule Types, H2 2017


List Of Table

List of Tables

Number of Products under Development for Ovarian Cancer, H2 2017

Number of Products under Development by Companies, H2 2017

Number of Products under Development by Universities/Institutes, H2 2017

Products under Development by Companies, H2 2017

Products under Development by Universities/Institutes, H2 2017

Number of Products by Stage and Target, H2 2017

Number of Products by Stage and Mechanism of Action, H2 2017

Number of Products by Stage and Route of Administration, H2 2017

Number of Products by Stage and Molecule Type, H2 2017

Ovarian Cancer-Pipeline by 3-V Biosciences Inc, H2 2017

Ovarian Cancer-Pipeline by 4SC AG, H2 2017

Ovarian Cancer-Pipeline by AB Science SA, H2 2017

Ovarian Cancer-Pipeline by AbbVie Inc, H2 2017

Ovarian Cancer-Pipeline by AbGenomics International Inc, H2 2017

Ovarian Cancer-Pipeline by Adaptimmune Therapeutics Plc, H2 2017

Ovarian Cancer-Pipeline by Adgero Biopharmaceuticals Holdings Inc, H2 2017

Ovarian Cancer-Pipeline by Advanced Cancer Therapeutics LLC, H2 2017

Ovarian Cancer-Pipeline by Advantagene Inc, H2 2017

Ovarian Cancer-Pipeline by Advenchen Laboratories LLC, H2 2017

Ovarian Cancer-Pipeline by Aeterna Zentaris Inc, H2 2017

Ovarian Cancer-Pipeline by Alethia Biotherapeutics Inc, H2 2017

Ovarian Cancer-Pipeline by AlfaSigma SpA, H2 2017

Ovarian Cancer-Pipeline by Alkermes Plc, H2 2017

Ovarian Cancer-Pipeline by Allist Shanghai Pharmaceutical Technology Co Ltd, H2 2017

Ovarian Cancer-Pipeline by Almac Discovery Ltd, H2 2017

Ovarian Cancer-Pipeline by Alpha Cancer Technologies Inc, H2 2017

Ovarian Cancer-Pipeline by Alteogen Inc, H2 2017

Ovarian Cancer-Pipeline by Altor BioScience Corp, H2 2017

Ovarian Cancer-Pipeline by Ambrx Inc, H2 2017

Ovarian Cancer-Pipeline by Amgen Inc, H2 2017

Ovarian Cancer-Pipeline by Amunix Operating Inc, H2 2017

Ovarian Cancer-Pipeline by Anavex Life Sciences Corp, H2 2017

Ovarian Cancer-Pipeline by ANP Technologies Inc, H2 2017

Ovarian Cancer-Pipeline by AntiCancer Inc, H2 2017

Ovarian Cancer-Pipeline by Antigen Express Inc, H2 2017

Ovarian Cancer-Pipeline by Antoxis Ltd, H2 2017

Ovarian Cancer-Pipeline by Aphios Corp, H2 2017

Ovarian Cancer-Pipeline by Aposense Ltd, H2 2017

Ovarian Cancer-Pipeline by Aprea AB, H2 2017

Ovarian Cancer-Pipeline by arGEN-X BV, H2 2017

Ovarian Cancer-Pipeline by ARMO Biosciences Inc, H2 2017

Ovarian Cancer-Pipeline by Armour Therapeutics Inc, H2 2017

Ovarian Cancer-Pipeline by ArQule Inc, H2 2017

Ovarian Cancer-Pipeline by Array BioPharma Inc, H2 2017

Ovarian Cancer-Pipeline by Arrien Pharmaceuticals LLC, H2 2017

Ovarian Cancer-Pipeline by Astellas Pharma Inc, H2 2017

Ovarian Cancer-Pipeline by Astex Pharmaceuticals Inc, H2 2017

Ovarian Cancer-Pipeline by AstraZeneca Plc, H2 2017

Ovarian Cancer-Pipeline by Atara Biotherapeutics Inc, H2 2017

Ovarian Cancer-Pipeline by Athenex Inc, H2 2017

Ovarian Cancer-Pipeline by AVEO Pharmaceuticals Inc, H2 2017

Ovarian Cancer-Pipeline by Avipep Pty Ltd, H2 2017

Ovarian Cancer-Pipeline by Basilea Pharmaceutica Ltd, H2 2017

Ovarian Cancer-Pipeline by Bavarian Nordic A/S, H2 2017

Ovarian Cancer-Pipeline by Bayer AG, H2 2017

Ovarian Cancer-Pipeline by BeiGene Ltd, H2 2017

Ovarian Cancer-Pipeline by Bio-Path Holdings Inc, H2 2017

Ovarian Cancer-Pipeline by BioCancell Ltd, H2 2017

Ovarian Cancer-Pipeline by BioMoti Ltd, H2 2017

Ovarian Cancer-Pipeline by Bionomics Ltd, H2 2017

Ovarian Cancer-Pipeline by BioNTech AG, H2 2017

Ovarian Cancer-Pipeline by Biscayne Pharmaceuticals Inc, H2 2017

Ovarian Cancer-Pipeline by Boehringer Ingelheim GmbH, H2 2017

Ovarian Cancer-Pipeline by Boston Biomedical Inc, H2 2017

Ovarian Cancer-Pipeline by Bristol-Myers Squibb Co, H2 2017

Ovarian Cancer-Pipeline by Caladrius Biosciences Inc, H2 2017

Ovarian Cancer-Pipeline by Calithera Biosciences Inc, H2 2017

Ovarian Cancer-Pipeline by CASI Pharmaceuticals Inc, H2 2017

Ovarian Cancer-Pipeline by Cavion LLC, H2 2017

Ovarian Cancer-Pipeline by CBT Pharmaceuticals Inc, H2 2017

Ovarian Cancer-Pipeline by Celgene Corp, H2 2017

Ovarian Cancer-Pipeline by Celldex Therapeutics Inc, H2 2017

Ovarian Cancer-Pipeline by Celleron Therapeutics Ltd, H2 2017

Ovarian Cancer-Pipeline by Cellular Biomedicine Group Inc, H2 2017

Single User License:
Report can be used by individual purchaser only

Site License: 
Report can be shared by unlimited users within one corporate location, e.g. a regional office

Corporate User License:  
Report can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company

To know more information on Purchase by Section, please send a mail to support@kenresearch.com

Companies

3-V Biosciences Inc

4SC AG

AB Science SA

AbbVie Inc

AbGenomics International Inc

Adaptimmune Therapeutics Plc

Adgero Biopharmaceuticals Holdings Inc

Advanced Cancer Therapeutics LLC

Advantagene Inc

Advenchen Laboratories LLC

Aeterna Zentaris Inc

Alethia Biotherapeutics Inc

AlfaSigma SpA

Alkermes Plc

Allist Shanghai Pharmaceutical Technology Co Ltd

Almac Discovery Ltd

Alpha Cancer Technologies Inc

Alteogen Inc

Altor BioScience Corp

Ambrx Inc

Amgen Inc

Amunix Operating Inc

Anavex Life Sciences Corp

ANP Technologies Inc

AntiCancer Inc

Antigen Express Inc

Antoxis Ltd

Aphios Corp

Aposense Ltd

Aprea AB

arGEN-X BV

ARMO Biosciences Inc

Armour Therapeutics Inc

ArQule Inc

Array BioPharma Inc

Arrien Pharmaceuticals LLC

Astellas Pharma Inc

Astex Pharmaceuticals Inc

AstraZeneca Plc

Atara Biotherapeutics Inc

Athenex Inc

AVEO Pharmaceuticals Inc

Avipep Pty Ltd

Basilea Pharmaceutica Ltd

Bavarian Nordic A/S

Bayer AG

BeiGene Ltd

Bio-Path Holdings Inc

BioCancell Ltd

BioMoti Ltd

Bionomics Ltd

BioNTech AG

Biscayne Pharmaceuticals Inc

Boehringer Ingelheim GmbH

Boston Biomedical Inc

Bristol-Myers Squibb Co

Caladrius Biosciences Inc

Calithera Biosciences Inc

CASI Pharmaceuticals Inc

Cavion LLC

CBT Pharmaceuticals Inc

Celgene Corp

Celldex Therapeutics Inc

Celleron Therapeutics Ltd

Cellular Biomedicine Group Inc

Celon Pharma SA

Celprogen Inc

Celsion Corp

Celyad SA

Ceronco Biosciences

CerRx Inc

Chipscreen Biosciences Ltd

Cielo Therapeutics Inc

Clovis Oncology Inc

CohBar Inc

Coherus BioSciences Inc

Commence Bio Inc

Compliment Corp

Corcept Therapeutics Inc

Critical Outcome Technologies Inc

Cyclacel Pharmaceuticals Inc

CytomX Therapeutics Inc

Cytori Therapeutics Inc

CZ BioMed Corp

DAE HWA Pharmaceutical Co Ltd

Deciphera Pharmaceuticals LLC

DEKK-TEC Inc

DelMar Pharmaceuticals Inc

Dr. Reddy's Laboratories Ltd

Ecrins Therapeutics SAS

Eisai Co Ltd

Eli Lilly and Co

Endocyte Inc

EntreChem SL

Epigen Biosciences Inc

EpiThany Inc

Epizyme Inc

Esperance Pharmaceuticals Inc

Exelixis Inc

F. Hoffmann-La Roche Ltd

Faron Pharmaceuticals Oy

Fate Therapeutics Inc

Forty Seven Inc

Fujifilm Holdings Corporation

Galena Biopharma Inc

GamaMabs Pharma SA

Gene Techno Science Co Ltd

Genelux Corp

Genentech Inc

Genisphere LLC

Genmab A/S

Genor BioPharma Co Ltd

Gilead Sciences Inc

GlaxoSmithKline Plc

Glenmark Pharmaceuticals Ltd

GlycoNex Inc

Glycotope GmbH

GP Pharm SA

Gradalis Inc

GW Pharmaceuticals Plc

Halozyme Therapeutics Inc

Hanmi Pharmaceuticals Co Ltd

Hemispherx Biopharma Inc

Horizon Pharma Plc

Ideaya Biosciences Inc

Ignyta Inc

Ildong Pharmaceutical Co Ltd

IMMD Inc

Immix BioPharma Inc

Immune Design Corp

Immune Pharmaceuticals Inc

Immunocore Ltd

ImmunoGen Inc

Immunomedics Inc

Immunovaccine Inc

IMPACT Therapeutics Inc

Imugene Ltd

Incyte Corp

Innate Pharma SA

Innovation Pharmaceuticals Inc

Inovio Pharmaceuticals Inc

Inventiva

Iovance Biotherapeutics Inc

ITUS Corp

Jiangsu Hengrui Medicine Co Ltd

Jiangsu Kanion Pharmaceutical Co Ltd

Johnson & Johnson

Juno Therapeutics Inc

Karyopharm Therapeutics Inc

Kazia Therapeutics Ltd

Kringle Pharma Inc

Kyowa Hakko Kirin Co Ltd

La Jolla Pharmaceutical Company

Laboratoire HRA Pharma SAS

Lantern Pharma Inc

LATITUDE Pharmaceuticals Inc

LegoChem Biosciences Inc

Lidds AB

Lixte Biotechnology Holdings Inc

Loxo Oncology Inc

Lycera Corp

Lymphocyte Activation Technologies SA

MabVax Therapeutics Holdings Inc

MacroGenics Inc

Madrigal Pharmaceuticals Inc.

Mateon Therapeutics Inc

MaxiVAX SA

Mebiopharm Co Ltd

MediaPharma SRL

MedImmune LLC

Medivir AB

Merck & Co Inc

Merck KGaA

Merrimack Pharmaceuticals Inc

Mersana Therapeutics Inc

Merus NV

Microlin Bio Inc

Millennium Pharmaceuticals Inc

Minerva Biotechnologies Corp

Moleculin Biotech Inc

MolMed SpA

Monopar Therapeutics LLC

Morphotek Inc

Mycenax Biotech Inc

NanoVector Inc

NantKwest Inc

Natco Pharma Ltd

NBE-Therapeutics AG

Nektar Therapeutics

Neovacs SA

Nerviano Medical Sciences Srl

Neurimmune Holding AG

NewLink Genetics Corp

Northwest Biotherapeutics Inc

Novartis AG

NovaTarg Therapeutics Inc

Noviga Research AB

Noxopharm Ltd

NuCana Plc

Oasmia Pharmaceutical AB

OBI Pharma Inc

Omeros Corp

Omnitura Therapeutics Inc

OncBioMune Pharmaceuticals Inc

Oncobiologics Inc

Oncodesign SA

Oncolix Inc

Oncolytics Biotech Inc

OncoMed Pharmaceuticals Inc

OncoResponse Inc

OncoTartis Inc

OncoTherapy Science Inc

Oncternal Therapeutics Inc

Ono Pharmaceutical Co Ltd

Opsona Therapeutics Ltd

Optimum Therapeutics LLC

ORCA Therapeutics BV

Oric Pharmaceuticals Inc

OSE Immunotherapeutics

Oxford BioMedica Plc

Pangaea Biotech SL

Patrys Ltd

PDS Biotechnology Corp

PEP-Therapy SAS

Pfizer Inc

Pharma Mar SA

PharmAust Ltd

Pharmicell Co Ltd

Plexxikon Inc

Polaris Pharmaceuticals Inc

Precision Biologics Inc

Propanc Biopharma Inc

Protheragen Inc

PsiOxus Therapeutics Ltd

PTC Therapeutics Inc

Puma Biotechnology Inc

Radius Health Inc

Recepta Biopharma SA

Rexahn Pharmaceuticals Inc

Rgenix Inc

Richter Gedeon Nyrt

Rigel Pharmaceuticals Inc

Rosetta Genomics Ltd

RS Research

Rubicon Biotechnology Inc

RXi Pharmaceuticals Corp

Samumed LLC

Sanofi

Sanofi Pasteur SA

SATT North SAS

Scancell Holdings Plc

Sellas Life Sciences Group Ltd

Senhwa Biosciences Inc

Sequoia Sciences Inc

Siamab Therapeutics Inc

Sierra Oncology Inc

Sigma-Tau SpA

Sillajen Biotherapeutics

Sitka Biopharma Inc

Soricimed Biopharma Inc

Sorrento Therapeutics Inc

Sotio AS

Starpharma Holdings Ltd

Sumitomo Dainippon Pharma Co Ltd

Sun Pharma Advanced Research Company Ltd

Supratek Pharma Inc

Susavion Biosciences Inc

Sutro Biopharma Inc

Syndax Pharmaceuticals Inc

Synthon Holdings BV

Syros Pharmaceuticals Inc

Tactiva Therapeutics LLC

Taiho Pharmaceutical Co Ltd

Takis Srl

TapImmune Inc

Targovax ASA

TC BioPharm Ltd

Tesaro Inc

The Female Health Company

TheraTarget Inc

Tocagen Inc

TRACON Pharmaceuticals Inc

Transgene SA

TVAX Biomedical Inc

Tyrogenex Inc

Unleash Immuno Oncolytics Inc

ValiRx Plc

Vascular Biogenics Ltd

Vectorite Biomedical Inc

Verastem Inc

VG Life Sciences Inc

ViiV Healthcare UK Ltd

ViraTherapeutics GmbH

Vyriad Inc

Zymeworks Inc